The 'three-parent baby' fertility doctor needs to stop marketing the procedure, FDA says
By Rachel Becker,
The Verge [cites Marcy Darnovsky]
| 08. 05. 2017
On Friday, FDA sent him a letter notifying him of his violations
The doctor who created a genetically modified “three-parent baby” has been reprimanded by the Food and Drug Administration for aggressively marketing the unapproved experimental procedure.
John Zhang, CEO of the New Hope Fertility Center in New York, famously combined the DNA of three people to help a mother who was a carrier for a genetic disease conceive an apparently healthy baby boy last year. Now, Zhang and his company are marketing the pricy procedure as the “first proven treatment for certain genetic disorders and a successful solution to age-related infertility.”
However, the FDA does not allow clinical research in people that would involve genetically modifying an embryo. And because Zhang’s technique and the one child it produced are both still in their infancy, we don’t know how well the treatment really works, or if it comes with any unforeseen consequences. On Friday, the FDA posted a letter to Zhang online, informing him that marketing the procedure is illegal, since the FDA hasn’t given him permission to...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
